Top Back to top

Cellular Therapy & Immunobiology Working Party: Call for participation DLI Study


We would like to invite you to participate in a retrospective study of the EBMT Cellular Therapy and Immunobiology Working Party regarding: Donor Lymphocyte Infusions (DLI) after haploidentical stem cell transplantation.

In this retrospective study, the outcomes of patients receiving DLI after T-cell replete haplo-SCT with post-transplantation cyclophosphamide will be evaluated, focusing either for prophylactic or for preemptive use.

The inclusion criteria are:

  • Adults (18 years)
  • Hematological malignancies
  • Received DLI post T-cell replete haplo-SCT with Pt-Cy approach
  • First DLI in EBMT transplant centres between January 2008 and December 2018

The exclusion criteria are:

  • Prior allogeneic HSCT (autologous HSCT permitted)
  • Disease of secondary origin or transformed

If you are interested in this study, please contact the study coordinator: Jorinde Hoogenboom ( and we can send you the study questionnaire and work instructions.